At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 39,680 enrolled
Drug / intervention
CVnCoV +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating CVnCoV, Placebo, and 1 other intervention for Covid19 and SARS-CoV-2. Completed, enrolled 39,680 participants across 46 sites in 10 countries.
Detailed Summary
The primary objective of the randomized observer-blinded phase 2b/3 part of this trial is to demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any severity in SARS-CoV-2 naïve participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, SARS-CoV-2
CountriesArgentina, Belgium, Colombia, Dominican Republic, Germany, Mexico, Netherlands, Panama, Peru, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionJun 2022
TodayJul 2026
First PostedDec 3, 2020
Enrollment StartDec 11, 2020
Primary CompletionJun 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.6 years ago
Interventions
CVnCoVbiological
Intramuscular (IM) injection.
Placebobiological
Intramuscular (IM) injection.
Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination programbiological
Intramuscular (IM) injection will be received as standard of care (SoC) outside the study.